The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Valeant's Japan sales performance.
Cosentyx, Skyrizi and Tremfya face increasing competition in the psoriasis market however, with a host of other new entrants including Eli Lilly’s Taltz (ixekizumab), Leo/Valeant’s Siliq (brodalumab) and
Bausch Health (formerly Valeant) has just launched a bid for the company on the premise that it will be able to kick start sales of Trulance, Synergy’s only-approved product,
Cosentyx was the first IL-17 inhibitor to reach the market and, while it has since been joined by rivals from Eli Lilly (Taltz) and Valeant (Siliq), is well ahead in
Valeant shares tumble after FDA rejection. A rejection by the US regulator for Valeant’s plaque psoriasis treatment. ... Valeant said in a statement that the FDA had not specified any clinical efficacy or safety shortcomings in its Complete Response
Add in additional IL-17 inhibitors for Eli Lilly and Valeant and the market for biologics for psoriasis is looking increasingly crowded, and a lot will depend on which of the
W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...